Late-breaking results support Kodiak's objective of every three-, four-, and five-month long-interval dosing of KSI-301 in patients with wet AMD
KSI-301 continues towards its development goals of demonstrating safety and efficacy (with over 250 injections given to over 100 patients with no intraocular inflammation) and now promising durability data
PR Newswire
PALO ALTO, Calif., Sept. 15, 2019